🔝🔟 #ASCO24 ✅OncoAlert🎯
#GI
x.com/OncoAlert/stat…
#PCSM
x.com/OncoAlert/stat…
#BLCSM #KCSM
x.com/OncoAlert/stat…
#MELSM
x.com/OncoAlert/stat…
#Palliative
x.com/OncoAlert/stat…
#BCSM
x.com/OncoAlert/stat…
#LEUSM
x.com/OncoAlert/stat…
#LCSM
x.com/OncoAlert/stat…

🩸 #ASCO24 Minimal Residual Disease #MRD Series🔥
📢#4600 #BLCSM
🎙️Dr. Joshua Linscott
🧬Urinary cfDNA (utDNA). PredicineBEACON personalized ultra-deep sequencing
🎯MRD can be detected accurately using utDNA prior to rTURBT
#liquidbiopsy OncoAlert ASCO
meetings.asco.org/abstracts-pres…

This May is #BladderCancerMonth24 and watch out for our weekly podcast on our website this Friday with our special guest Jonathan Rosenberg MD who gives updates in ADCs including:

⭐The future of EV + pembro
⭐SG + other ADCs
⭐Managing toxicities

Here's a 30 sec preview 🎙️

#blcsm

EV-302 Subgroup Analyses presented by Michiel van der Heijden #GU24 #blcsm ASCO

🔷 EV+P improved PFS & OS regardless of cisplatin-eligibility and PD-L1 expression
🔷EV+P improved PFS & OS regardless of presence of liver, visceral, or LN metastases
🔷 EV+P improved PFS and OS across all

#Oncología de Centroamérica
🇭🇳 🇵🇦 🇨🇷 🇬🇹 🇩🇴
#pcsm by FLoscoMD 🇦🇷
#blcsm by me 🇦🇷
#LATAM #UroOncoIAF Urooncologia.arg

At #BLADDR23 , Paul Sargos discusses the role of adjuvant RT after RC for #MIBC . Positive surgical margins in 4-15% of pts having RC, PSM excluded in adjuvant immunotherapy trials. Locoregional recurrence 41-68% with pT3-4 <10 LN or PSM, and LRR impacts MFS #blcsm #radonc

🆕 Standard of care in 1st line therapy in Urothelial Carcinoma #blcsm
Thanks Andrea Apolo, M.D. for shed light in the field!
OncoAlert ESMO - Eur. Oncology #ESMO23

role of PET/TC scan in #blcsm by Antonio Cigliola #GU24
no differences in accuracy between CT and PET to detect LNI OncoDaily

Great pleasure to have Shilpa Gupta in Urooncologia.arg 🇦🇷...
Bladder cancer #blcsm

UNITE study: EV after avelumab maintenance .
#blcsm #GU24 ASCO blatam uro
coming the ARON2EV study by Fernando Sabino, MD, PhD

Promising data on biomarker for urothelial cancers (NMIBC MIBC UTUC) both for screening, treatment and follow-up. Excellent talk by Prof Rik Bryan at #FOCUS23

#bladdercancer #blcsm

At #bladdr23 , Vérane Achard discusses the role of RT for non muscle invasive bladder cancer. Initial RCT for pT1G3 urothelial dz did not show PFS benefit, but NRG Oncology 0926 phII trial of max TURBT + 61.2Gy/34# with cis or MMC/5FU showed 3yr freedom from RC of 88%. #blcsm #radonc

Final Count-down to the 2nd Editon of #LATAM preceptorship in Urothelial Carcinoma #Blcsm
Instituto Alexander Fleming Fundación Cáncer Merck
Juan Pablo Sade FLoscoMD Dr. Tomás Soulé Juan Camean Gustavo Villoldo

Ellegant presentation by Sumanta K. Pal, MD, FASCO about What Can Other Disease Sites Teach Us About Practical Implications of ICI in Urothelial Carcinoma #blcsm ? #GU24 OncoAlert OncoDaily

#1 T-6 #ASCO 24 ! Have been watching out for all the #curated lists on #lcsm #bcsm #mmsm #melsm #blcsm #kcsm and #community oncology! Ft. Aakash Desai, MD, MPH Paolo Tarantino Dipesh Uprety MD FACP Mike Thompson, MD, PhD, FASCO Tarek Haykal, MD, MHS Toni Choueiri, MD
#ASCO Featured Voices, add more if you find them!
Omar Abdihamid Oncologist @Garissa Cancer Center,

End of a 3⃣ day #LATAM preceproship in Bladder cancer #blcsm at Instituto Alexander Fleming 🇦🇷 🇧🇷 🇵🇪 🇲🇽 🇨🇱🇪🇨
Thanks to all #UroOncoIAF staff Juan Pablo Sade FLoscoMD Federico Waisberg Dr. Tomás Soulé Gustavo Villoldo Joaquin Chemi Roberto Villalba Bachur Fernandez Candia Gaston Fundación Cáncer

At the final #bladder23 session, #WhereIsHoskin discusses oligometastatic bladder cancer and the dearth of evidence guiding management. In European Urology Open Science systematic review, only 315 patients across 8 studies. European Urology Delphi consensus study should ensure common language #blcsm

Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer

🔗buff.ly/4bihcsT

#LiquidBiopsy #TumourDNA
#BladderCancer #BLCSM Guro Elisabeth Lind

Beautiful work from Matt Galsky and #IMvigor130 team published today in Cell Reports Medicine and mentioned by William Y. Kim in his fantastic #BladderCancer #immunotherapy #blcsm talk at #GU24

cell.com/cell-reports-m…

#2 T-6 #ASCO24 ! Have been watching out for all the #curated lists on #lcsm #bcsm #mmsm #melsm #blcsm #kcsm and #community oncology! Ft. Aakash Desai, MD, MPH Paolo Tarantino Dipesh Uprety MD FACP Mike Thompson, MD, PhD, FASCO Tarek Haykal, MD, MHS Toni Choueiri, MD